Menu
Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with ...
- Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases
- Approval of Giotrif® is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell carcinoma of the lung
- Afatinib is already approved in more than 60 countries for the treatment of patients with EGFR mutation-positive NSCLC*
(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the http://me-newswire.net//news/17544/en...
Dans la même rubrique :
Mardi 28 Octobre 2025 - 19:45 Tchad : Atelier de Formation sur l'Utilisation des Images par le Volet des Standards des Ménages (EHCVM) |
Lundi 27 Octobre 2025 - 08:47 Tchad : Le Paysage Aouk-Keïta, un patrimoine naturel à préserver |
Lundi 13 Octobre 2025 - 13:25 The Evolution of Premium Financial Data Marketplaces |
